Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association CongressGlobeNewsWire • 06/14/24
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 06/05/24
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24Newsfile Corp • 06/04/24
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 06/03/24
Bio-Path Holdings to Present Data at 2024 European Hematology Association CongressGlobeNewsWire • 05/24/24
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 05/23/24
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024GlobeNewsWire • 05/08/24
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 04/19/24
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 04/18/24
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) PatientsGlobeNewsWire • 04/18/24
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23Newsfile Corp • 03/27/24
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024GlobeNewsWire • 03/01/24
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia PatientsGlobeNewsWire • 01/10/24